Stefani Wolff - 30 Apr 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: EVP and COO
Issuer ticker: NRIX
Reported as of: 30 Apr 2023
Net transaction value: -$3,378
SEC form: 4
Accepted by SEC: 02 May 2023, 16:33:54 UTC
Prior SEC filing: 15 Feb 2023
Next SEC filing: 11 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Christine Ring, as Attorney-in-Fact for Stefani Wolff

Key filing fact

Stefani Wolff filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 02 May 2023.

Key facts

This page summarizes Stefani Wolff's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 May 2023, 16:33.

Change

Previous filing in this sequence was filed on 15 Feb 2023.
Current net transaction value: -$3,378.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRIX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +962
Change %: +18%
Price: $0.000000
Shares after: 6,455
Date: 30 Apr 2023
Ownership: Direct
Footnotes: F1

NRIX transaction

Common Stock

Sale

Transaction value: $3,378
Shares: -342
Change %: -5.3%
Price: $9.88
Shares after: 6,113
Date: 01 May 2023
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -962
Change %: -8.3%
Price: $0.000000
Shares after: 10,582
Date: 30 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 962
Exercise price: $0.000000
Footnotes: F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Stefani Wolff is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.

Footnote F2

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Footnote F3

Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Footnote F4

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Footnote F5

The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

Footnote F6

RSUs do not expire; they either vest or are canceled prior to the vest date.